Literature DB >> 16896935

High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts.

A Solini1, E Santini, M Nannipieri, E Ferrannini.   

Abstract

AIMS/HYPOTHESIS: Atherosclerosis is particularly aggressive in patients with diabetes. Hyperhomocysteinaemia causes oxidative stress and cytokine secretion: its atherogenic effect is mediated by an enhanced inflammatory response. Matrix metalloproteinases (MMPs) regulate extracellular matrix degradation and remodelling, and contribute to the vulnerability of the atherosclerotic lesion. Fibroblasts contribute to collagen biosynthesis and participate in plaque remodelling via expression and release of MMP2 and MMP9. To explore the role of hyperhomocysteinaemia in cellular pathways involved in plaque growth and stability in diabetic patients, we studied the effect of hyperhomocysteinaemia in human fibroblasts grown in the presence of normal or high glucose concentrations.
MATERIALS AND METHODS: In fibroblasts of five normal subjects, grown at 5.5 or 22 mmol/l glucose and treated with homocysteine, we determined: (1) MMP2, MMP9 and tissue inhibitor of metalloproteinases (TIMP)-1 (an MMP inhibitor) production by western blot analysis; (2) their activity by zymography; (3) TGFB1 expression by real-time PCR; and (4) TGFB, fibronectin and IL6 release by ELISA.
RESULTS: Hyperhomocysteinaemia increased the production and enzymatic activity of MMP2 and MMP9, the effect being more pronounced in high glucose. Conversely, TIMP1 production was reduced by hyperhomocysteinaemia in both conditions, especially in high glucose. Hyperhomocysteinaemia also stimulated IL6 release, at least in part through nuclear factor-kappaB activation. TGFB1 expression was not affected by hyperhomocysteinaemia either in normal or in high glucose. CONCLUSIONS/
INTERPRETATION: Homocysteine upregulates the MMP-TIMP pathway and IL6 release, the effect being stronger in the presence of high glucose. These actions of homocysteine may contribute to the increased atherogenesis observed in diabetic patients with poor metabolic control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896935     DOI: 10.1007/s00125-006-0377-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

Review 1.  Matrix metalloproteinases and coronary artery diseases.

Authors:  Uichi Ikeda; Kazuyuki Shimada
Journal:  Clin Cardiol       Date:  2003-02       Impact factor: 2.882

2.  Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation.

Authors:  Xiaohua Jiang; Fan Yang; Hongmei Tan; Dan Liao; Robert M Bryan; Jaspreet K Randhawa; Rolando E Rumbaut; William Durante; Andrew I Schafer; Xiaofeng Yang; Hong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-06       Impact factor: 8.311

3.  Remodeling of the adventitia during coronary arteriogenesis.

Authors:  Wei-Jun Cai; Sophie Koltai; Elisabeth Kocsis; Dimitri Scholz; Sawa Kostin; Xuegang Luo; Wolfgang Schaper; Jutta Schaper
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08-29       Impact factor: 4.733

4.  High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts.

Authors:  A Solini; P Chiozzi; S Falzoni; A Morelli; R Fellin; F Di Virgilio
Journal:  Diabetologia       Date:  2000-10       Impact factor: 10.122

5.  Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases.

Authors:  J B Knox; G K Sukhova; A D Whittemore; P Libby
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

6.  The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Christian A Seemayer; Charles F Reich; Renate E Gay; Beat A Michel; Adriano Fontana; Steffen Gay; David S Pisetsky; Oliver Distler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

7.  Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: relation with nutritional and other factors.

Authors:  E Diakoumopoulou; N Tentolouris; E Kirlaki; D Perrea; E Kitsou; M Psallas; D Doulgerakis; N Katsilambros
Journal:  Nutr Metab Cardiovasc Dis       Date:  2005-04-13       Impact factor: 4.222

Review 8.  Elevated plasma homocysteine as risk factor for peripheral arterial disease--what is the evidence?

Authors:  Lloyd M Taylor
Journal:  Semin Vasc Surg       Date:  2003-09       Impact factor: 1.000

9.  Effect of homocysteine on cytokine production by human endothelial cells and monocytes.

Authors:  S Dalal; S M Parkin; S Homer-Vanniasinkam; A Nicolaou
Journal:  Ann Clin Biochem       Date:  2003-09       Impact factor: 2.057

10.  Vitamin C or Vitamin B6 supplementation prevent the oxidative stress and decrease of prostacyclin generation in homocysteinemic rats.

Authors:  M M Mahfouz; F A Kummerow
Journal:  Int J Biochem Cell Biol       Date:  2004-10       Impact factor: 5.085

View more
  13 in total

1.  Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.

Authors:  Kristen A Wieghaus; Erwin P Gianchandani; Milton L Brown; Jason A Papin; Edward A Botchwey
Journal:  Tissue Eng       Date:  2007-10

2.  Myocardial fibrosis and TGFB expression in hyperhomocysteinemic rats.

Authors:  Lamia Raaf; Christophe Noll; Mohamed El Hadi Cherifi; Jane-Lise Samuel; Claude Delcayre; Jean-Maurice Delabar; Yasmina Benazzoug; Nathalie Janel
Journal:  Mol Cell Biochem       Date:  2010-10-12       Impact factor: 3.396

Review 3.  Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart.

Authors:  Jia Zhao; Rushil Randive; James A Stewart
Journal:  World J Diabetes       Date:  2014-12-15

4.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

5.  Changes in biological behaviors of rat dermal fibroblasts induced by high expression of MMP9.

Authors:  Sheng-Neng Xue; Juan Lei; Diao-Zhu Lin; Chuan Yang; Li Yan
Journal:  World J Emerg Med       Date:  2014

6.  Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia.

Authors:  Karni S Moshal; Darryl C Zeldin; Srinivas D Sithu; Utpal Sen; Neetu Tyagi; Munish Kumar; William M Hughes; Naira Metreveli; Dorothea S E Rosenberger; Mahavir Singh; Thomas P Vacek; Walter E Rodriguez; Adeagbo Ayotunde; Suresh C Tyagi
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

7.  Cardiac fibroblast-dependent extracellular matrix accumulation is associated with diastolic stiffness in type 2 diabetes.

Authors:  Kirk R Hutchinson; C Kevin Lord; T Aaron West; James A Stewart
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  Folic acid mitigates angiotensin-II-induced blood pressure and renal remodeling.

Authors:  Sathnur B Pushpakumar; Sourav Kundu; Naira Metreveli; Utpal Sen
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

9.  The biological behaviors of rat dermal fibroblasts can be inhibited by high levels of MMP9.

Authors:  Sheng-Neng Xue; Juan Lei; Chuan Yang; Diao-Zhu Lin; Li Yan
Journal:  Exp Diabetes Res       Date:  2012-04-22

10.  T2DiACoD: A Gene Atlas of Type 2 Diabetes Mellitus Associated Complex Disorders.

Authors:  Jyoti Rani; Inna Mittal; Atreyi Pramanik; Namita Singh; Namita Dube; Smriti Sharma; Bhanwar Lal Puniya; Muthukurussi Varieth Raghunandanan; Ahmed Mobeen; Srinivasan Ramachandran
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.